Sheila Che
Family · Arcadia, CANPI 1275200636
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,115 of the $3,462 with a category attached, or 90.0%. It is spread thinly across 41 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,550 and has fallen 82.1% since, to $457 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$479
- Gilead$400
- Incyte Corporation$372
- AbbVie$277
- Eisai Inc.$176
- Exelixis Inc.$170
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,11590%
- Education$34710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 9 | $479 |
| Gilead | 9 | $400 |
| Incyte Corporation | 11 | $372 |
| AbbVie | 12 | $277 |
| Eisai Inc. | 6 | $176 |
| Exelixis Inc. | 4 | $170 |
| Pfizer | 3 | $150 |
| Bayer | 6 | $127 |
| Syndax Pharmaceuticals, Inc. | 1 | $120 |
| Merck | 5 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $82 |
| Seagen Inc. | 2 | $57 |
| Taiho Oncology, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Sobi, Inc | 2 | $51 |
| Immunogen, Inc. | 2 | $50 |
| Recordati_rare_diseases_inc. | 2 | $47 |
| Lilly USA, LLC | 2 | $45 |
| Astellas Pharma US Inc | 2 | $42 |
| Blueprint Medicines Corporation | 2 | $42 |
| Genentech USA, Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $41 |
| Karyopharm Therapeutics Inc. | 2 | $36 |
| Genmab U.S., Inc. | 1 | $32 |
| Novartis | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Puma Biotechnology, Inc. | 1 | $30 |
| Novo Nordisk | 1 | $27 |
| Sanofi | 1 | $26 |
| Fennec Pharmaceuticals, Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $25 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Morphosys, US Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Novocure Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,462 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 12 | $159,380 |
| Letrozole | 34 | $795 |
| Anastrozole | 30 | $529 |
| Hydroxyurea | 16 | $331 |
| Tamoxifen Citrate | 11 | $111 |
| Alendronate Sodium | 22 | $105 |
Paid to pharmacies, not to this prescriber.
Other family in Arcadia
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.